Equity Overview
Price & Market Data
Price: $1.35
Daily Change: -$0.14 / 10.37%
Range: $1.35 - $1.55
Market Cap: $147,026,880
Volume: 298,290
Performance Metrics
1 Week: -9.40%
1 Month: -8.16%
3 Months: -56.73%
6 Months: -78.54%
1 Year: -81.58%
YTD: -56.31%
Company Details
Employees: 155
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase 11 loss-of-function mutations for treating lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.